Wells Fargo lowered the firm’s price target on Zimmer Biomet to $110 from $112 and keeps an Equal Weight rating on the shares. The firm is updating its model to refelct Zimmer Biomet’s ERP disruption. Wells also lowered its 2024 EPS and revenue estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- Zimmer Biomet initiated with a Peer Perform at Wolfe Research
- Zimmer Biomet guidance update an ‘unwelcome negative,’ says Truist
- Zimmer news to erase some of recent rally, says Citi
- Zimmer Biomet’s ERP issue likely to pressure sales, EPS estimates, says Stifel